Cancer-Produced Metabolites of 5-Lipoxygenase Induce Tumor-Evoked Regulatory B Cells via Peroxisome Proliferator–Activated Receptor α

Breast cancer cells facilitate distant metastasis through the induction of immunosuppressive regulatory B cells, designated tBregs. We report in this study that, to do this, breast cancer cells produce metabolites of the 5-lipoxygenase pathway such as leukotriene B4 to activate the peroxisome proliferator–activated receptor α (PPARα) in B cells. Inactivation of leukotriene B4 signaling or genetic deficiency of PPARα in B cells blocks the generation of tBregs and thereby abrogates lung metastasis in mice with established breast cancer. Thus, in addition to eliciting fatty acid oxidation and metabolic signals, PPARα initiates programs required for differentiation of tBregs. We propose that PPARα in B cells and/or tumor 5-lipoxygenase pathways represents new targets for pharmacological control of tBreg-mediated cancer escape.

[1]  J. Peters,et al.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention , 2012, Nature Reviews Cancer.

[2]  Donald E Ingber,et al.  Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. , 2012, The Journal of clinical investigation.

[3]  J. Lederer,et al.  Targeting regulatory T cells in cancer. , 2011, Cancer research.

[4]  Sui Huang,et al.  Regulation of inflammation in cancer by eicosanoids. , 2011, Prostaglandins & other lipid mediators.

[5]  L. Su,et al.  Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. , 2011, Cancer research.

[6]  M. Sayegh,et al.  Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. , 2011, The Journal of clinical investigation.

[7]  R. Murase,et al.  Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis , 2011, Breast Cancer Research and Treatment.

[8]  S. Cuzzocrea,et al.  Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury , 2011, Expert opinion on therapeutic targets.

[9]  J. Auwerx,et al.  Lack of IL‐2 in PPAR‐α‐deficient mice triggers allergic contact dermatitis by affecting regulatory T cells , 2011, European journal of immunology.

[10]  R. Wersto,et al.  Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. , 2011, Cancer research.

[11]  J. Rokach,et al.  5-oxo-ETE is a major oxidative stress-induced arachidonate metabolite in B lymphocytes. , 2011, Free radical biology & medicine.

[12]  W. Leonard,et al.  Thymic Stromal Lymphopoietin Is a Key Mediator of Breast Cancer Progression , 2011, The Journal of Immunology.

[13]  M. V. Suresh,et al.  Leukotriene B4 Is a Physiologically Relevant Endogenous Peroxisome Proliferator-activated Receptor-α Agonist* , 2010, The Journal of Biological Chemistry.

[14]  G. Pani,et al.  Metastasis: cancer cell’s escape from oxidative stress , 2010, Cancer and Metastasis Reviews.

[15]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[16]  O. Werz,et al.  5-Lipoxygenase inhibitors: a review of recent developments and patents , 2010, Expert opinion on therapeutic patents.

[17]  K. Rainsford.  Ibuprofen: pharmacology, efficacy and safety , 2009, Inflammopharmacology.

[18]  A. Sampson.  FLAP inhibitors for the treatment of inflammatory diseases. , 2009, Current opinion in investigational drugs.

[19]  S. Briest,et al.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. , 2009, Cancer research.

[20]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[21]  Birgitta Sander,et al.  High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes , 2009, BMC Immunology.

[22]  C. Vachon,et al.  Allergic pulmonary inflammation promotes the recruitment of circulating tumor cells to the lung. , 2008, Cancer research.

[23]  D. Gabrilovich,et al.  Tumor escape mechanism governed by myeloid-derived suppressor cells. , 2008, Cancer research.

[24]  E. Chi,et al.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. , 2008, Immunity.

[25]  Jilly F. Evans,et al.  What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. , 2008, Trends in pharmacological sciences.

[26]  C. Perreault,et al.  T Regulatory Cells Control Numbers of NK Cells and CD8α+ Immature Dendritic Cells in the Lymph Node Paracortex1 , 2007, The Journal of Immunology.

[27]  K. Morimura,et al.  Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.

[28]  K. Hunter,et al.  Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. , 2007, Experimental and molecular pathology.

[29]  P. Allavena,et al.  Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.

[30]  D. Taub,et al.  Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. , 2006, Blood.

[31]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[32]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[33]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[34]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[35]  R. Knutsen,et al.  Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor–null mice , 2003, Nature Medicine.

[36]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[37]  G. Davı̀,et al.  5‐Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  T. Moody,et al.  Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  S. Biswal,et al.  Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886 , 2001 .

[40]  O. Werz,et al.  Reactive oxygen species released from granulocytes stimulate 5-lipoxygenase activity in a B-lymphocytic cell line. , 2000, European journal of biochemistry.

[41]  X. Ding,et al.  Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. , 1999, Biochemical and biophysical research communications.

[42]  C. Myers,et al.  Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[44]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[45]  P. Biberfeld,et al.  Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. , 1995, European journal of biochemistry.

[46]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[47]  Y. Fujii‐Kuriyama,et al.  A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase. , 1993, The Journal of biological chemistry.

[48]  P. Sterk,et al.  Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. , 1993, The American review of respiratory disease.

[49]  E. Sigal.  The molecular biology of mammalian arachidonic acid metabolism. , 1991, The American journal of physiology.

[50]  J. Reddy,et al.  Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens , 1980, Nature.

[51]  C. Perreault,et al.  T Regulatory Cells Control Numbers of NK Cells and CD8 Immature Dendritic Cells in the Lymph Node Paracortex , 2007 .

[52]  W. Wahli,et al.  The PPARalpha-leukotriene B4 pathway to inflammation control. , 1996, Nature.